Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma: Morphological appraisal with a comprehensive review of differential diagnoses - PubMed

Affiliations

• PMID: 32108620
• DOI: 10.4103/IJPM.IJPM_877_19

Review

Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma: Morphological appraisal with a comprehensive review of differential diagnoses

Ziad El-Zaatari et al. Indian J Pathol Microbiol. 2020 Feb.

Abstract

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an autosomal dominant syndrome wherein affected individuals are at risk for the development of cutaneous leiomyomas, early-onset multiple uterine leiomyomas, and an aggressive subtype of renal cell cancer. HLRCC is caused by germline mutations in the fumarate hydratase (FH) gene, which inactivates the enzyme and alters the function of the tricarboxylic acid/Krebs cycle. This article reviews the hitherto described morphologic features of HLRCC-associated renal cell carcinoma (RCC) and outlines the differential diagnosis and ancillary use of immunohistochemistry and molecular diagnostics for these tumors. The morphologic spectrum of HLRCC-associated RCC is wide and histologic features, including tumor cells with prominent nucleoli, perinucleolar halos, and multiple architectural patterns within the same tumor, which are suggestive of this diagnosis. FH immunohistochemistry in conjunction with genetic counseling and germline FH testing are the important parameters for detection of this entity. These kidney tumors warrant prompt treatment as even smaller sized lesions can demonstrate aggressive behavior and systemic oncologic treatment in metastatic disease should, if possible, be part of a clinical trial. Screening procedures in HLRCC families should preferably be evaluated in large cohorts.

Keywords: Collecting duct carcinoma; Hereditary leiomyomatosis and renal cell carcinoma; fumarate hydratase; papillary type 2 renal cancer; targeted therapy.

Conflict of interest statement

None

Similar articles

• Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.

  Sanz-Ortega J, Vocke C, Stratton P, Linehan WM, Merino MJ. Sanz-Ortega J, et al. Am J Surg Pathol. 2013 Jan;37(1):74-80. doi: 10.1097/PAS.0b013e31825ec16f. Am J Surg Pathol. 2013. PMID: 23211287 Free PMC article.

• Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry.

  Chen YB, Brannon AR, Toubaji A, Dudas ME, Won HH, Al-Ahmadie HA, Fine SW, Gopalan A, Frizzell N, Voss MH, Russo P, Berger MF, Tickoo SK, Reuter VE. Chen YB, et al. Am J Surg Pathol. 2014 May;38(5):627-37. doi: 10.1097/PAS.0000000000000163. Am J Surg Pathol. 2014. PMID: 24441663 Free PMC article.

• Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment.

  Menko FH, Maher ER, Schmidt LS, Middelton LA, Aittomäki K, Tomlinson I, Richard S, Linehan WM. Menko FH, et al. Fam Cancer. 2014 Dec;13(4):637-44. doi: 10.1007/s10689-014-9735-2. Fam Cancer. 2014. PMID: 25012257 Free PMC article. Review.

Cited by

• Hereditary Leiomyomatosis and Renal Cell Cancer: Recent Insights Into Mechanisms and Systemic Treatment.

  Zhang C, Li L, Zhang Y, Zeng C. Zhang C, et al. Front Oncol. 2021 May 25;11:686556. doi: 10.3389/fonc.2021.686556. eCollection 2021. Front Oncol. 2021. PMID: 34113573 Free PMC article. Review.

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal